Genmab AS's coffers are set to swell again after US regulators granted another approval for Darzalex, further cementing the Johnson & Johnson-partnered drug's dominant position in the multiple myeloma field.
Following a priority review granted in May, the US Food and Drug Administration has approved Darzalex (daratumumab) in combination with...







